Download PDF
Zeitschrift für Komplementärmedizin 2017; 09(02): 34-38
DOI: 10.1055/s-0043-107822
Praxis
Cannabinoide
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Cannabinoide in der Palliativmedizin

Jens Keßler
Subject Editor:
Further Information

Publication History

Publication Date:
06 July 2017 (online)

    Permissions and Reprints

Summary

Die Diskussion um Cannabinoide wird emotional geführt, oft werden die medizinische Anwendung und der nicht medizinische Konsum vermischt. Zusammen mit Vorurteilen gegenüber der Substanzgruppe und einer abwertenden Wortwahl führt das zum schambesetzten Umgang mit diesem Thema bei betroffenen Patienten in der Palliativsituation und zur Verunsicherung der Behandelnden.

Der Artikel fasst die seit Januar 2017 geltenden gesetzlichen Rahmenbedingungen zusammen, erläutert die verfügbaren Produkte und deren Verordnungsmodalitäten. Basierend auf der aktuellen Studienlage werden die möglichen Einsatzgebiete mit palliativmedizinischem Fokus erörtert.

Keywords

Cannabinoide - Dronabinol - Nabilon - Cannabidiol - Palliativmedizin
 

  • Literatur

  • 1 Tai SY, Lee CY, Wu CY. et al. Symptom severity of patients with advanced cancer in palliative care unit: longitudinal assessments of symptoms improvement. BMC palliative care 2016; 15: 32
    CrossrefPubMedSearch in Google Scholar
  • 2 Ford BM, Tai S, Fantegrossi WE. et al. Synthetic pot: not your grandfather’s marijuana. Trends Pharmacol Sci 2017; 38 (03) 257-276
    CrossrefPubMedSearch in Google Scholar
  • 3 Cressey D. The cannabis experiment. Nature 2015; 524 7565 280-283
    CrossrefPubMedSearch in Google Scholar
  • 4 Kilmer B. Recreational cannabis – minimizing the health risks from legalization. N Engl J Med 2017; 376 (08) 705-707
    CrossrefPubMedSearch in Google Scholar
  • 5 Zhang MW, Ho RC. The Cannabis Dilemma: A Review of Its Associated Risks and Clinical Efficacy. J Addict 2015;
    CrossrefSearch in Google Scholar
  • 6 Costa B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem Biodivers 2007; 4 (08) 1664-1677
    CrossrefPubMedSearch in Google Scholar
  • 7 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015; 313 (24) 2456-2473
    CrossrefPubMedSearch in Google Scholar
  • 8 Müller-Vahl KG. F. Medizinisches Cannabis: Die wichtigsten Änderungen. Dtsch Arztebl. 2017; 114 (08) A352-356
    Search in Google Scholar
  • 9 Hua T, Vemuri K, Pu M. et al. Crystal structure of the human cannabinoid receptor CB1. Cell 2016; 167 (03) 750-762.e14
    CrossrefPubMedSearch in Google Scholar
  • 10 Zajicek JP, Hobart JC, Slade A. et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012; 83 (11) 1125-1132
    CrossrefPubMedSearch in Google Scholar
  • 11 Jawahar R, Oh U, Yang S. et al. A systematic review of pharmacological pain management in multiple sclerosis. Drugs 2013; 73 (15) 1711-1722
    CrossrefPubMedSearch in Google Scholar
  • 12 Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012; 109 (29/30) 495-501
    PubMedSearch in Google Scholar
  • 13 Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2012; 10 (04) 487-492
    CrossrefPubMedSearch in Google Scholar
  • 14 Hernandez SL, Sheyner I, Stover KT. et al. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp Palliat Care 2015; 32 (01) 5-7
    CrossrefPubMedSearch in Google Scholar
  • 15 May MB, Glode AE. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res 2016; 8: 49-55
    PubMedSearch in Google Scholar
  • 16 Benze G, Geyer A, Alt-Epping B. et al. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients: a systematic review]. Schmerz 2012; 26 (05) 481-499
    CrossrefPubMedSearch in Google Scholar
  • 17 Smith LA, Azariah F, Lavender VT. et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; (11) Cd009464
    PubMedSearch in Google Scholar
  • 18 Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV / AIDS. Cochrane Database Syst Rev 2013; (04) Cd005175
    PubMedSearch in Google Scholar
  • 19 Beal JE, Olson R, Laubenstein L. et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10 (02) 89-97
    CrossrefPubMedSearch in Google Scholar
  • 20 Robson PJ. Therapeutic potential of cannabinoid medicines. Drug Test Anal 2014; 6 (01/02) 24-30
    CrossrefPubMedSearch in Google Scholar
  • 21 Brisbois TD, de Kock IH, Watanabe SM. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011; 22 (09) 2086-2093
    CrossrefPubMedSearch in Google Scholar
  • 22 de Vries M, van Rijckevorsel DC, Wilder-Smith OH. et al. Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opin Pharmacother 2014; 15 (11) 1525-1534
    CrossrefPubMedSearch in Google Scholar
  • 23 Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain 2013; 29 (02) 162-171
    CrossrefPubMedSearch in Google Scholar
  • 24 Portenoy RK, Ganae-Motan ED, Allende S. et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012; 13 (05) 438-449
    CrossrefPubMedSearch in Google Scholar
  • 25 Johnson JR, Burnell-Nugent M, Lossignol D. et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39 (02) 167-179
    CrossrefPubMedSearch in Google Scholar
  • 26 Carter GT, Flanagan AM, Earleywine M. et al. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Care 2011; 28 (05) 297-303
    CrossrefPubMedSearch in Google Scholar
  • 27 Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012; 12 (06) 436-444
    CrossrefPubMedSearch in Google Scholar
  • 28 Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol 2016; 23 (02) S8-S14
    PubMedSearch in Google Scholar
  • 29 Davis MP. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. J Natl Compr Canc Netw 2016; 14 (07) 915-922
    CrossrefPubMedSearch in Google Scholar
  • 30 Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6 (01) 35-42
    CrossrefPubMedSearch in Google Scholar
  • 31 Maida V, Daeninck PJ. A user’s guide to cannabinoid therapies in oncology. Curr Oncol 2016; 23 (06) 398-406
    CrossrefPubMedSearch in Google Scholar
  • 32 Mucke M, Carter C, Cuhls H. et al. [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety]. Schmerz 2016; 30 (01) 25-36
    CrossrefPubMedSearch in Google Scholar